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Cardiovascular diseases (CVDs) are responsible for almost 17 million deaths worldwide, with hypertension being a 
major contributor to over half of these cases (55%).1 Two thirds 
(66%) of deaths among people >85 years of age are CVD 
related, and this age group presents high rates of hypertension. 
Hypertension is associated with increased risks of coronary 
heart disease, stroke, peripheral vascular disease, cognitive 
impairment, renal impairment, and visual impairment among 
others.2–4 Although the benefits of lowering elevated blood 
pressure (BP) levels are conclusive among younger population 
groups,5 there is an ongoing debate about the benefits of treat-
ment and optimal therapeutic BP target among octogenarians. 
Evidence for a negative association between BP with mortality 
and CVD events supports the view that lower BP may be asso-
ciated with better outcomes.5–8 There is disagreement about 
how low the target BP should be set among octogenarians, 
with clinical trials suggesting different systolic BP (SBP) tar-
gets, including <120,9 <130,5 <140,10 or <150 mm Hg.11 Other 
authors12,13 suggested that among octogenarians both lower 
and higher values can lead to adverse events. Consistent with 
this evidence, current guidelines favor a more relaxed thera-
peutic target for BP in octogenarians (SBP <150 mm Hg).14,15 
This ongoing disagreement about hypertension management in 
very old people underlines the need for further investigations 
to ascertain optimal BP levels in community-living octogenar-
ians, the population subgroup in whom hypertension is most 
prevalent. Thus, the first objective of this study was to estimate 
the relationship of SBP ranges with mortality among octoge-
narians. Given recent cross-sectional evidence about under-
diagnosis of hypertension in community populations,16 the 
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second objective of this study was to evaluate trends in hyper-
tension prevalence, awareness, treatment, and control among 
people younger than and older than 80 years of age.
Methods
The study uses data from the English Longitudinal Study of Ageing 
(ELSA), a prospective study of a nationally representative sample of 
adults aged ≥50 years living in private households in England. The 
ELSA sample was drawn from 3 years (1998, 1999, and 2001) of 
the Health Survey for England (HSE) survey (wave 0). The origi-
nal ELSA sample was followed-up biannually, including 2002/2003 
(wave 1), 2004/2005 (wave 2), 2006/2007 (wave 3), 2008/2009 (wave 
4), 2010/2011 (wave 5), and 2012/2013 (wave 6). A broad range of 
health, demographic, socioeconomic, and lifestyle data were col-
lected at each survey, including clinical measurements carried out by 
trained nurses every 4 years (wave 0, wave 2, wave 4, and wave 6). 
At waves 3 and 4, the study was replenished with new study par-
ticipants from the HSE to maintain the size and representativeness 
of the study. This approach accounts for variation in eligible par-
ticipants included in the analyses across different waves. A detailed 
description of methods, response rates, and sampling procedures can 
be found elsewhere.4,17,18 The analytic sample for this study included 
24 699 participants aged ≥50 years at wave 0 and who were eligible 
to be included in the ELSA study. Participants gave their consent to 
participate in the study and ethical approval was granted from the 
London Multicentre Research Ethics Committee.
Outcome Measures
Mortality outcomes were all-cause mortality and CVD-related mortal-
ity. These measures were based on mortality data up to February 2012, 
the latest date when the ELSA study mortality data were updated from 
the National Health Service Central Data Registry (NHSCR) records. 
NHSCR contains computerized records of all NHS patients, including 
reliable data of everyone who has died in England. ELSA also records 
NHSCR data on participants’ main cause of death (using International 
Classification of Diseases Ninth Revision and International 
Classification of Diseases Tenth Revision coding), which was used 
to develop the CVD-related outcome measure. A small number of 
participants who did not give permission to check NHSCR records 
(n=458), but who were identified as being deceased from other sources 
(fieldwork or next of kin) were included in the analysis.
Exposure Variables
BP Measurement
All participants were eligible to have their BP measured. Three separate 
BP readings were taken 1 minute apart on seating participants, by the 
nurse using the Omron HEM-907 monitor (Dinamap at baseline). BP data 
from baseline were Omron adjusted to allow comparability with following 
years using previous equations.19 The study used the mean of the second 
and third SBP and diastolic BP (DBP) readings. To avoid regression to the 
mean bias from using only baseline BP values, and following Lewington 
et al’s20 suggestions, the study calculated the average BP across baseline 
(wave 0), wave 2, and wave 4 data. Wave 6 data were not used in the main 
analyses because of the lack of updated mortality data beyond wave 5. 
SBP measurements were then used to classify participants into 8 groups in 
increments of 10 mm Hg (<110, 110–119, 120–129, 130–139, 140–149, 
150–159, 160–169, and ≥170 mm Hg). DBP values were used to clas-
sify participants into 7 groups with an increment of 10 mm Hg (<50, 
50–59, 60–69, 70–79, 80–89, 90–99, and ≥100 mm Hg).
Hypertension Prevalence, Treatment, Monitoring,  
and Control
For comparability with recent US-based evidence21 within a UK 
context, the study explored trends in hypertension prevalence, aware-
ness, treatment, and control. Participants were considered as hyper-
tensive if they had SBP ≥140 mm Hg and DBP ≥90 mm Hg, reported 
a previous physician-diagnosed hypertension, and were current users 
of antihypertensive medication. Participants reporting a previous 
physician-diagnosed hypertension or if they reported current taking 
of antihypertensive medication were categorized as being aware of 
having hypertension. Participants who were on current antihyper-
tensive medication were categorized as a treatment group. Finally, 2 
BP-controlled hypertension categories were developed: (1) SBP/DBP 
of <150/90 mm Hg and (2) SBP/DBP of <140/90 mm Hg reflecting 
Eight Joint National Committee (JNC-8) and, respectively, JNC-7 
treatment recommendations. In addition, a self-reported BP monitor-
ing variable was included to reflect the proportion of hypertensive 
people with a BP consultation in the past 12 months.
Covariates
Several factors known to be associated with hypertension and mortal-
ity were included as covariates. Age was included as a continuous 
variable and sex as a binary variable. Smoking classified participants 
into never, ex-smokers, and current smokers. Participants were clas-
sified into underweight (body mass index [BMI], <18.5 kg/m2), opti-
mal (BMI, 18.5–24.9 kg/m2), overweight (BMI, 25–29.9 kg/m2), and 
obese (BMI ≥30 kg/m2), according to their baseline BMI. Data about 
the type and amount of physical activity participation were used to 
group participants into sedentary or low and moderate or vigorous 
activity. Social class was defined as a binary variable, grouping par-
ticipants into manual and nonmanual occupations. Long-standing 
illness (including CVD, type 2 diabetes mellitus, arthritis, cancer, 
liver disease, and chronic kidney disease) was included as a binary 
variable. Depression has been associated with increased hypertension 
risk,22 and it was assessed as a continuous variable using the 12-item 
General Health Questionnaire. Total cholesterol value was included 
as a continuous variable. Finally, antihypertensive medication intake 
was included as a binary variable. C-reactive protein and frailty mea-
sures were also considered initially but excluded from final analyses 
as they did not influence the association between SBP with mortality.
Statistical Analysis
Study sample characteristics were analyzed using descriptive sta-
tistics. Descriptive statistics were used to denote the prevalence of 
hypertension and the proportion of people with hypertension aware-
ness, treated, monitored, and controlled. Participants contributed 
follow-up time (person-years) from the time of entry into the study 
until the date of death, or the end date of the study or the date of last 
known contact. Cox proportional hazard models were used to esti-
mate the association between BP categories with all-cause mortality 
adjusting for study covariates. Separate analyses were conducted for 
hypertension-treated participants, those aged ≥80 years, and the full 
sample. Because non-CVD mortality can be considered a competing 
event for CVD-related mortality, competing risks regression analy-
ses were used to estimate hazard ratios and 95% confidence inter-
vals of CVD-related mortality for categories of SBP and DBP. In all 
analyses, the reference group for SBP was 120 to 129 mm Hg and for 
DBP it was 70 to 79 mm Hg. An SBP range of 120 to 129 mm Hg is 
considered optimal in adult population,23 and it has been chosen as 
the reference category in our study. Consistent with previous stud-
ies,24,25 the nadir range in our study was defined as the SBP range 
associated with the lowest mortality estimates, after which lowest 
values tended to be associated with higher mortality rates. To mini-
mize the potential for reverse causality bias, the analyses excluded 
participants who died within 6 months from study baseline and within 
60 days26 from a follow-up BP measurement (n=209). The hazards 
proportionality assumption was tested using Schoenfeld residuals 
against survival time, which revealed no violation of this assumption. 
Models were adjusted for age, sex, BMI, long-standing illness, cho-
lesterol values, BP treatment, smoking, physical activity, depression, 
DBP, and social class. The decision to adjust for DBP was based on 
suggestions that the relation of SBP and CVD mortality varies with 
DBP values.27 Multiple imputation with chained equations was used 
to handle missing data using 10 imputed data sets and including all 
study variables in the imputation model. Planned sensitivity analy-
ses were conducted that included the exclusion of patients with CVD 
diagnosis at baseline, and the use of restricted SBP categories (<120, 
120–129, 130–139, 140–149, 150–159, and >160 mm Hg). Following 
 at King's College London on June 29, 2016http://hyper.ahajournals.org/Downloaded from 
Dregan et al  Hypertension and Mortality in Octogenarians  99
the study by Aparicio et al,28 we also used Cox regression to estimate 
mortality risk associated with BP expressed as a continuous predictor. 
We evaluated whether there was a deviation from linearity using the 
Wald test for nonlinear hypotheses and, if present, estimated whether 
a quadratic term improved goodness-of-fit. In all analyses, a 2-sided 
P<0.05 was chosen as the criterion for statistical significance. All 
analyses were carried out using STATA version 13. Because SBP is 
a stronger predictor of mortality risk compared with DBP in people 
>60 years of age,29 only the results for SBP are discussed here (DBP 
results are available from the authors). The study presents the results 
for patients aged 50 to 79 years for comparative purposes only, with 
the main focus being on the results for octogenarians.
Results
The ELSA included 24 699 participants with a mean of 7 
(range, 0–15) years as follow-up years. Table 1 shows the 
characteristics of the participants at baseline by 10 mm Hg 
SBP categories. Mean age was greater for higher SBP values. 
Participants with highest SBP values were generally older, 
presented higher rates of chronic illness, and were more likely 
to be obese, from poor social background, and physically 
inactive. Participants with the lowest SBP levels were more 
likely to be female, younger, underweight, and present higher 
rates of smoking and depressive symptoms. The amount of 
missing data in the analyses varied from around 6% (ie, social 
class) to 42% (ie, physical activity levels).
Table 2 shows the longitudinal trends in awareness, treat-
ment, and control of hypertension in all study participants, and 
those aged ≥80 years, contrasted with those aged <80 years. 
Rates of awareness of hypertension, treatment of hyperten-
sion, as well as the proportion of treated participants who 
achieved recommended SBP targets generally increased over 
time. Similar trends emerged when participants were divided 
into ages <80 years and ≥80 years, with the latter presenting 
a steady improvement in all domains during the study period. 
Although a higher proportion of people aged ≥80 years were 
aware of being hypertensive and were on treatment compared 
with those aged <80 years, a lower proportion achieved rec-
ommended BP targets (<150/90 mm Hg).
Patterns of longitudinal changes in mean BP levels for 
treated and untreated participants are illustrated in Figure 1. 
A declining trend was observed in mean SBP among treated 
octogenarians from 147 mm Hg in 1998/2001 to 134 mm Hg 
in 2012/2013. Thus, there was an absolute difference in mean 
SBP >12 years period of −12 mm Hg (95% confidence interval, 
−15 to −9; P<0.001). Untreated octogenarians showed an initial 
decline in mean SBP (135 mm Hg) to 2008/2009, followed by 
a modest increase in mean SBP (137 mm Hg) to 2012/2013.
The results of Cox regression analyses for octogenarians 
are presented in Figure 2. Although not statistically significant, 
Table 1. Study Population Characteristics at Baseline According to Hypertension Subtype
Systolic Blood  
Pressure, mm Hg
<110  
(n=683)
110–119 
(n=1904)
120–129 
(n=3098)
130–139 
(n=3545)
140–149 
(n=2823)
150–159 
(n=1700)
160–169  
(n=843)
≥170  
(n=785)
Sex–female 489 (72) 1070 (56) 1674 (54) 1820 (51) 1436 (51) 928 (55) 471 (56) 448 (64)
Age, (M, SD) 58 (10) 59 (10) 59 (10) 62 (10) 63 (10) 66 (10) 67 (11) 70 (11)
Body mass index, kg/m2
  Under weight (<18.5) 8 (2) 15 (1) 21 (1) 14 (1) 11 (1) 14 (1) 3 (1) 6 (1)
  Optimal (18.5–24.99) 190 (47) 503 (38) 750 (33) 737 (27) 527 (24) 321 (24) 140 (21) 146 (27)
  Overweight (25–29.99) 153 (38) 580 (43) 1041 (46) 1259 (46) 1037 (47) 608 (46) 305 (47) 242 (45)
  Obese (30+) 54 (13) 243 (18) 467 (20) 729 (26) 637 (28) 389 (29) 205 (31) 149 (27)
Current smoker
  Never 268 (40) 753 (41) 1246 (41) 1372 (39) 1017 (37) 638 (38) 314 (38) 263 (39)
  Ex-smoker 242 (37) 779 (40) 1288 (42) 1552 (44) 1300 (47) 775 (46) 371 (45) 299 (44)
  Current smoker 155 (23) 355 (19) 529 (17) 585 (17) 465 (17) 265 (16) 141 (17) 118 (17)
Long-standing illness* 268 (40) 791 (42) 1359 (44) 1768 (50) 1476 (53) 942 (56) 478 (58) 418 (61)
Antihypertensive drugs 98 (15) 328 (17) 518 (17) 812 (23) 771 (28) 542 (33) 295 (36) 261 (38)
Manual vs nonmanual 245 (38) 721 (39) 1191 (39) 1470 (43) 1214 (44) 796 (49) 368 (47) 325 (50)
Total cholesterol (M, SD) 5.58 (1)  5.76 (1)  5.82 (1) 6.01 (1) 6.02 (1) 6.18 (1) 6.11 (1) 6.28 (1)
Diastolic blood  
pressure, (M, SD)
65 (6) 69 (6) 73 (7) 76 (7) 79 (7) 81 (8) 84 (8) 88 (11)
Depression 133 (20) 261 (14) 403 (13) 411 (12) 322 (12) 199 (12) 113 (14) 82 (12)
Physical activity
  Minimum 130 (48) 337 (41) 596 (42) 801 (47) 684 (50) 426 (52) 257 (58) 215 (57)
  Medium 77 (29) 291 (35) 454 (32) 525 (30) 411 (30) 246 (30) 131 (29) 107 (28)
  Vigorous 63 (23) 202 (24) 356 (26) 392 (23) 275 (20) 148 (18) 57 (13) 56 (15)
Figures are frequencies (column percent). M indicates mean; and n, number.
*Long-standing illness include cardiovascular disease, type 2 diabetes mellitus, arthritis, cancer, liver disease, and chronic kidney disease.
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adjusted competing risks analyses among treated older partici-
pants suggested that the association between SBP and CVD 
mortality might follow a J-shaped curve, with increased point 
estimates for both low and high extremes of SBP. The low-
est event rate SBP range was between 140 and 149 mm Hg 
(hazard ratio, 1.04; 95% confidence interval, 0.60–1.78). The 
association of SBP with all-cause mortality seemed to follow 
an inverse J-shaped curve with the critical nadir SBP range 
between 160 and 169 mm Hg (0.78, 0.51–1.21).
Among participants aged 50 to 79 years (Figure 3), the 
association of SBP with both CVD and all-cause mortality 
followed a J-shaped curve. The critical nadir SBP range for 
CVD and all-cause mortality risk among treated participants 
was between 140 and 149 mm Hg and 130 and 139 mm Hg, 
respectively. Similar patterns were revealed in the combined 
treated and untreated analyses. None of the associations 
reached statistical significance level.
Sensitivity Analyses
Sensitivity analyses that excluded patients with CVD diag-
nosis at baseline and that used restricted SBP categories 
validated the patterns of the association between SBP with 
mortality outcomes in primary analyses (Figures S1–S4 in the 
online-only Data Supplement). Analyses based on continuous 
BP measures (Table 3) identified that a model incorporating a 
quadratic term yielded improved goodness-of-fit than a linear 
model among treated octogenarians (P<0.001). These analy-
ses revealed a modestly significant association between all-
cause mortality with SBP (β, −0.04, −0.09 to −0.00) among 
treated octogenarians. Because the interpretation of coeffi-
cients from quadratic regression do not have a straightforward 
interpretation, supplementary plots are provided in Figure S4. 
These plots suggest that the association between SBP with all-
cause mortality among treated octogenarians is U-shaped with 
the nadir at 167 mm Hg. A similar trend was observed for the 
50 to 79 years of age subgroup with the nadir at 143 mm Hg.
Discussion
In this 12-year prospective study, the mean SBP among octo-
genarians decreased by 13 mm Hg between 1998/2001 and 
2012/2013. A similar trend of lower magnitude (7 mm Hg) was 
observed among the 50 to 79 years old participants. After an initial 
increment from baseline to 2004, the prevalence of hypertension 
remained constant at around 70% among treated octogenarians, 
compared with around 50% in the 50- to 79-year-old group. 
Hypertension awareness rates were higher among octogenarians 
compared with those aged 50 to 79 years; however, hypertension 
treatment and BP monitoring rates were similar. Using the BP 
target of <150/90 mm Hg, around 41% of treated octogenarians 
would be classified as having uncontrolled hypertension, a 23% 
lower figure compared with the target of <140/90 mm Hg sug-
gested by traditional guidelines. One possible explanation for the 
high proportion of octogenarians with uncontrolled hypertension 
is that in deciding whether to lower an older patient’s BP level 
a clinician may rely on multiple health indicators, knowledge 
about the patient’s BP history and their own clinical experience. 
Also, faced with differing empirical evidence clinicians may 
be reluctant to set specific BP targets for very old participants. 
Although not statistically significant, all-cause mortality tended 
to be higher at low-SBP ranges, and CVD mortality was higher at 
both extreme low- and high-SBP ranges. Thus, our findings are 
suggestive of a J-curve association between SBP with all-cause 
Table 2. Longitudinal Trends in Self-Reported Awareness, Treatment, Monitoring, and Control of Hypertension From 1998/2001 to 
2012/2013
Survey Year*
Hypertension 
n (% of Total)
Aware of  
Hypertension  
n (% of Hypertensive)
Treated and Aware 
n (% of Aware) BP Monitored
Control Among Treated
<150/90 mm Hg;  
n (% of Treated)
<140/90 mm Hg;  
n (% of Treated)
Total
  1998 (n=24699) 8907 (36) 6431 (72) 4422 (69) 1043 (16) 2059 (47) 1432 (32)
  2004 (n=8619) 4871 (57) 3796 (78) 2918 (77) 2046 (54) 1518 (52) 1122 (38)
  2008 (n=10012) 5423 (54) 4378 (81) 3480 (79) 3976 (91) 1951 (56) 1491 (43)
  2012 (n=8492) 4826 (57) 3918 (80) 3588 (92) 3636 (93) 2275 (63) 1782 (50)
Octogenarians
  1998 (n=1755) 979 (56) 712 (73) 569 (80) 103 (14) 292 (51) 209 (37)
  2004 (n=1083) 710 (66) 561 (79) 497 (89) 481 (86) 221 (44) 155 (31)
  2008 (n=1117) 794 (71) 693 (87) 614 (89) 599 (86) 309 (50) 226 (37)
  2012 (n=1251) 883 (71) 795 (90) 750 (94) 714 (90) 445 (59) 355 (47)
Age <80 y
  1998 (n=22944) 7928 (35) 5719 (72) 3853 (67) 940 (16) 1767 (46) 1223 (32)
  2004 (n=7536) 4161 (55) 3235 (78) 2421 (75) 1565 (48) 1297 (54) 967 (40)
  2008 (n=8895) 4629 (52) 3685 (80) 2866 (78) 3377 (92) 1642 (57) 1265 (44)
  2012 (n=7241) 3943 (54) 3123 (79) 2838 (91) 2922 (94) 1830 (64) 1427 (50)
BP indicates blood pressure; and n, number.
*The surveys year were: 1998/2001, 2004/2005, 20082009, 2012/2013.
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mortality among community-living octogenarians, although con-
ventional significance levels were not reached. This suggestion is 
supported by the nonlinear association observed between contin-
uous SBP measures with all-cause mortality among treated octo-
genarians. Our study identified an association of SBP with CVD 
mortality among the 50 to 79 years old participants mainly at 
higher extremes of SBP.
The lack of significant association between SBP and mor-
tality among treated octogenarians may suggest a beneficial 
role for antihypertensive therapy in survival.30 It is also possible 
that the study was insufficiently powered to allow detection of 
small variations in mortality events at the extreme levels of SBP 
among octogenarians. It might also be possible that among octo-
genarians differences in mortality events may become important 
at even higher (ie, >185 mm Hg) or lower (<100 mm Hg) SBP 
cut points than we evaluated.31 These suggestions underline the 
importance of further prospective studies with larger popula-
tions of octogenarians to verify and expand this study findings. 
The nonlinear relationship between SBP with all-cause mortal-
ity challenges the view that lower SBP values will generally be 
associated with better outcomes6 and supports recent sugges-
tions that lower BP is not necessarily better among octogenar-
ians.32 In accord with recent guidelines for less aggressive BP 
treatment target in octogenarians,14 the lowest mortality rates 
in treated octogenarians emerged for SBP ranges of 140 to 149 
mm Hg (CVD) and 160 to 169 mm Hg (all-cause mortality).
Longitudinal changes in hypertension prevalence, awareness, 
treatment, and control among community-living octogenarians 
are not well described, but the trends for the 50 to 79 years of 
age people are similar to findings based on earlier cross-sectional 
studies.21,33–35 Evidence about BP monitoring trends among 
community-living octogenarians is scarce, and this study findings 
imply improved practice because the introduction of the Quality 
and Outcomes Framework in April 2004.The suggestion of an 
inverse J-curve association between SBP with all-cause mortal-
ity is supportive of earlier longitudinal studies with octogenari-
ans.36,37 Studies38,39 with younger populations suggested increased 
all-cause mortality associated with high-SBP ranges. Our study 
confirms these findings for the 50 to 79 years old people, but 
not among octogenarians implying age different prognostic out-
comes associated with similar SBP ranges. In a Finnish cohort of 
people >85 years of age, Matilla et al13 found increased mortal-
ity rates associated with low-SBP and lower mortality rates for 
SBP values >160 mm Hg, as suggested by our study performed 
in a UK context. A meta-analysis of randomized trials12 found 
no association between hypertension treatment and all-cause 
mortality in octogenarians. Our study findings of no significant 
association between SBP levels with mortality among octogenar-
ians seem to support this evidence. The Hypertension in the Very 
Elderly Trial (HYVET) recommended an SBP target of 150/80 
mm Hg among treated older people,11 which is supported by this 
study evidence that among treated octogenarians the nadir SBP 
range for CVD mortality was around 140 to 149 mm Hg. A recent 
clinical trial9 suggested beneficial effects of lower SBP (<120 
mm Hg) on mortality in patients >50 years of age and at high 
risk of CVD. Our findings based on a more representative sample 
of community-dwelling older people cautions against lowering 
SBP levels <110 mm Hg among octogenarians.
Strengths and Weaknesses
This study has several strengths including prospective 
design, national representative sample, multiple SBP ranges, 
Figure 1. Patterns of longitudinal changes 
in mean systolic (A) and diastolic (B) blood 
pressures.
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and validated mortality data. All study participants had their 
BP measured with a similar instrument and time frame, and 
the values were averaged over multiple time points reducing 
the risk of residual dilution bias.40 As with most observa-
tional data, there are also important shortcomings. Reverse 
causality is common in observational designs, and we cannot 
exclude the possibility that undetected disease at baseline 
may partially account for the findings. This study minimized 
this bias by adjusting for chronic illness at baseline and by 
excluding events within 6 months from study start date or 
within 60 days from BP measurements. ELSA study partici-
pants are well characterized in general which allowed us to 
adjust for important covariates; however, residual confound-
ing (ie, patient choice and healthcare quality) remains a pos-
sibility. Selection and confounding by indication are other 
sources of concern. The longitudinal nature of this study 
Figure 2. Adjusted hazard ratios (HR) for mortality by systolic blood pressure (SBP) levels among total (A, n=2692) and treated (B, n=1299) 
octogenarians. CI indicates confidence interval.
Figure 3. Adjusted hazard ratios (HR) for mortality by systolic blood pressure (SBP) levels among total (A, n=22007) and treated (B, n=6311) 
people aged 50 to 79 years.
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ensured that people with both lower and higher BP levels, as 
well as treated and untreated hypertension, were included in 
the study and followed-up over time. Moreover, the analyses 
adjusted for both antihypertensive treatment and baseline 
CVD, further minimizing the possibility of confounding 
by indication.41 The study also used multiple imputation 
to impute values for participants with missing data, which 
further minimized the impact of selection and attrition bias 
Table 3. Adjusted Unstandardized Coefficients Relating Continuous Systolic Blood Pressure Measure to All-Cause 
and Cardiovascular Mortality
Study Outcomes E/N*
All
E/N
Treated
†β (95% CI) P Trend‡ Β (95% CI) P Trend
Octogenarians
  All-cause mortality
   Linear 1612/2692 −0.01 (−0.06 to 0.03) 0.456 750/1299 −0.05 (−0.09 to −0.01) 0.041
   Quadratic 1612/2692 0.00 (−0.00 to 0.00) 0.614 750/1299 0.00 (−0.00 to 0.00) 0.071
  Cardiovascular mortality
   Linear 597/2692 0.00 (−0.06 to 0.06) 0.925 301/1299 −0.02 (−0.09 to 0.04) 0.453
   Quadratic 597/2692 0.00 (−0.00 to 0.00) 0.873 301/1299 0.00 (−0.00 to 0.00) 0.456
<80 y of age
  All-cause mortality
   Linear 3347/22 007 −0.06 (−0.08 to −0.04) 0.001 1360/6311 −0.06 (−0.09 to −0.03) 0.001
   Quadratic 3347/22 007 0.00 (0.00 to 0.00) 0.001 1360/6311 0.00 (0.00 to 0.00) 0.001
  Cardiovascular mortality
   Linear 976/22 007 −0.06 (−0.10 to −0.03) 0.001 461/6311 −0.08 (−0.12 to −0.05) 0.001
   Quadratic 976/22 007 0.00 (0.00 to 0.00) 0.001 461/6311 0.00 (0.00 to 0.00) 0.001
CI indicates confidence intervals.
*E/N=events and frequencies.
†β=unstandardized coefficients.
‡P value for trend.
Figure 4. Fractional polynomial plots presenting the quadratic relationship between continuous systolic blood pressure (SBP) with total 
(A) and treated (B) cardiovascular disease (CVD) mortality and total (E) and treated (F) all-cause mortality among octogenarians (left) and 
the quadratic relationship between continuous SBP with total (C) and treated (D) CVD mortality and total (G) and treated (H) all-cause 
mortality among participants <80 years of age (right).
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on study findings. The small number of events toward the 
extremes of BP values may have possibly resulted in insuf-
ficient power to determine precise estimates for mortality 
risk among these groups. Additional analyses that reduced 
the number of SBP subgroups (ie, <120, 120–129, 130–139, 
140–149, 150–159, and >159 mm Hg) validated, however, 
the study’s main findings (data available from the authors). 
The study findings also need to be considered in the context 
of an arbitrary reference category, and deviation from over-
all population mean has been suggested as an alternative.28 
Using deviation from population mean modeling with our 
data revealed similar patterns of association to the primary 
analyses (data available from the authors). As Hosmer et al42 
suggested that the interpretation of the estimated coefficients 
from deviations from mean coding is not as easy or clear as 
when reference cell coding is used, we included the find-
ings based on the latter modeling here. Although participants 
were requested to show the label of the medicines taken to 
the interviewer, we cannot exclude the possibility for poor 
medication adherence, and no information was collected on 
the treatment regimens (ie, dosage, type, and duration). As 
our study participants’ BP was assessed in their own home, 
white coat effect or masked hypertension concerns are pos-
sibly minimal here.
In conclusion, we identified improving trends in hyper-
tension awareness, treatment, and BP monitoring with age. 
Although the increment in the proportion of treated octoge-
narians with controlled hypertension was encouraging, a sub-
stantial number had uncontrolled hypertension. The declining 
trend in mean SBP values in people younger than and older 
than 80 years of age may reflect both improved hyperten-
sion management and positive lifestyle behavioral changes. 
The latter supports the value of evaluating a potential role of 
lifestyle interventions for hypertension management among 
octogenarians. The apparent sharp increase in mortality rates 
associated with SBP ranges <110 and ≥170 mm Hg, sup-
port a wider range of SBP targets and treatment initiation for 
octogenarians. Although our findings corroborate with recent 
clinical recommendations for a more flexible approach to BP 
management among older people, they need confirmation 
with routinely collected data and randomized trials. The lack 
of statistical association may reflect a more restricted role for 
BP on mortality in people who survive into old age or inade-
quate study power warranting future investigations with larger 
samples.
Perspectives
In summary, our findings imply significant progression in 
hypertension management and monitoring among octo-
genarians. These improvements seem to coincide with the 
introduction of Quality and Outcomes Framework program, 
supporting the value of similar public health policies target-
ing very old people. The study findings support a more indi-
vidualized approach to treatment initiation and optimal BP 
targets among octogenarians. The challenges of implementing 
clinical trials to confirm these findings may be overcome by 
the use of routinely collected primary care data that possess 
greater external validity. Future studies are needed to also con-
sider clinical (ie, heart disease and stroke) and patient-centred 
outcomes (ie, quality of life and functioning) associated with 
different SBP targets.
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What Is New?
•	 First prospective study >10 years focusing on community-dwelling oc-
togenarians.
•	New findings about mortality risk associated with different systolic blood 
pressure categories.
What Is Relevant?
•	Despite improved hypertension management, a large proportion of treat-
ed octogenarians have uncontrolled hypertension.
•	All-cause mortality events among octogenarians increased with low but 
not high extremes of systolic blood pressure.
•	Among treated octogenarians, the association between systolic blood pres-
sure with all-cause mortality is better described by a nonlinear function.
Summary
Hypertension treatment, awareness, and monitoring improved 
among octogenarians to a greater extent than for those aged 50 to 
79 years. The findings propose a more relaxed approach to blood 
pressure targets among octogenarians, and warn against systolic 
blood pressure values <110 mm Hg.
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